1. Generics Bulletin
  2. >>Products

A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets

Firm Highlights LAI Olanzapine, As Trial Results Come Nine Months Ahead Of Schedule

 
• By Dave Wallace

Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.

Finger pushing innovation button
Another of Teva’s innovative assets has delivered results • Source: Shutterstock

Teva will doubtless be pleased with the reaction to its latest first-quarter results. In the days that followed the firm’s 8 May announcement of its Q1 2024 financials – coupled with a simultaneous disclosure of positive trial data, ahead of schedule, for its TEV-’749 long-acting injectable olanzapine candidate developed with partner MedinCell – the firm’s share price jumped by around 15% to more than $16 per share.

Analyst interest was focused on the olanzapine results, with Teva president and CEO Richard Francis explaining: “we had the data readout on the efficacy of this [SOLARIS Phase III pivotal] study, and it met its primary and secondary endpoints on all dose groups versus placebo

Key takeaways:

  • Teva has released earlier-than-expected positive trial results for its MedinCell-partnered TEV-’749 olanzapine long-acting injectable.

  • Meanwhile, the firm’s Uzedy long-acting injectable risperidone is on track to hit sales estimates of $80m this year.

  • Teva’s generics business grew by 9% in Q1, including 8% growth in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.